Novartis receives European licence for Mayzent®
(WorldNews Health)

Licence based on Phase III EXPAND trial data showing siponimod delayed disease progression, slowed the advance of physical symptoms and positively impacted cognition in a broad SPMS patient population [i],[ii],[iii] SPMS is characterised by a progressive accumulation of disability over time, affecting approximately a third of people living with MS[iv],[v],[vi] Until now, there have been limited management options available following an SPMS diagnosis[vii] London, UK, January 20, 2020 - Novartis today announced that the European Medicines Agency (EMA) has granted a licence for the use of Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple...